Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

The growth of AI in the healthcare sector is already having real-world impacts and promises a step-change in future care.

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).